Tipifarnib for recurrent and/or metastatic head and neck squamous cell carcinoma with HRAS mutations

Mutations in the HRAS proto-oncogene occur in 4% to 8% of patients with recurrent and/or metastatic HNSCC. Tipifarnib is a farnesyltransferase inhibitor that disrupts HRASfunction. The multinational phase 2 study KO-TIP-001 found encouraging activity of tipifarnib for R/M HNSCC with HRAS mutations.